Latest news with #Grail
Chicago Tribune
4 days ago
- Health
- Chicago Tribune
Rush now offers a blood test to help detect more than 50 types of cancer, as other health systems remain wary
Jack Welter didn't feel sick when he agreed to take a new blood test that looks for multiple types of cancer. But, approaching 60, he thought it couldn't hurt. To his surprise, the test came back positive. Welter then underwent multiple rounds of follow-up tests, and ultimately, doctors found cancer in his throat. The now 61-year-old Elkhart, Indiana, resident endured radiation and chemotherapy in 2023 and is now cancer-free. 'Without that test, I still would have had (cancer), obviously, but it might not have appeared for another year or more,' said Welter, who is expecting his first grandchild. 'Early detection is the key to success.' In recent years, the blood test, called Galleri, and others like it, have been gaining momentum among doctors who use them to help detect cancers that otherwise might go unnoticed until patients become ill. Now, at least one local health system, Rush University System for Health, has decided to start offering Galleri to patients widely in hopes of finding cancer early, when it's easier to treat. The test has not yet been approved by the U.S. Food and Drug Administration and is not covered by most health insurance plans. At Rush, it will cost most people $749 out-of-pocket. Providers at other local health systems have expressed wariness about offering the test broadly at this point, given those concerns and others. But Rush leaders felt it was important to move forward with the test, given its potential life-changing benefits for patients and because of its performance in clinical trials, said Dr. Lisa Stempel, director of the high-risk cancer screening program at Rush. 'The goal of all screening is to find cancer early when we can treat it,' said Stempel, who noted that 1 in 3 people will get cancer in their lifetimes. 'It's such a simple test in the fact that it can find so many cancers and the fact that it can find it in early stages is what's extremely exciting to me.' The test works by identifying DNA in the bloodstream that's shed by cancer cells. It can detect a cancer signal shared by more than 50 types of cancer, and it can also reveal roughly where in the body the cancer might be. A positive result is not the same as a diagnosis. If a patient gets a positive result, the patient must undergo additional testing, such as CT scans or PET scans, to help assess if they really have cancer. There's a 43% chance that a positive test result will be cancer, according to a study from Grail, the company that makes the Galleri test. The test has a false positive rate of 0.5% among patients who don't have cancer, meaning about 1 out of every 200 people who take the test and don't have cancer might still get a positive result. The test is only available by prescription, and it's recommended annually by Grail for people at higher risk of cancer, such as those ages 50 and older. Rush is also offering it to younger adults with risk factors such as a family history of cancer, smoking, diabetes or obesity. If a patient gets a positive result but doctors can't find any cancer, Grail offers a second test to the patient free of charge. That's what happened to Welter, the Indiana patient who had throat cancer. The first time he took the test, it came back positive for cancer somewhere between his chest and head, he said. But more traditional follow-up tests didn't turn up any cancer. He then took a second, free Galleri test about six months later and, again, it was positive. He underwent more testing, and the second time around, doctors found the cancer. 'At that point in time it was so small they really couldn't pinpoint it,' Welter said of doctors' efforts to find the cancer after his first Galleri test. Welter has been speaking to doctors at Rush about his experience in recent months as part of their training to offer the tests to patients widely. Welter said he hasn't been paid by Grail nor Rush. 'To me it's amazing the test could actually find something like that,' Welter said. Not everyone, however, is as gung-ho about the test. Though health systems in other parts of the U.S. are also offering Galleri, some Chicago-area health systems and providers say they don't believe the test is ready for prime time. Northwestern Medicine is not systematically offering the Galleri test at this point, with a spokesperson saying, 'The technology isn't sufficiently sensitive and specific enough for us to use this as a screening tool at this time.' Feighanne Hathaway, a genetic counselor at UChicago Medicine, said she also has a number of concerns. For one, she worries that the out-of-pocket cost creates more disparities in health care. She also worries that the test may be less adept at picking up signals for early-stage cancers than later stage ones, raising questions about its usefulness and value. A Grail study found that 48% of confirmed cancers detected by Galleri were stages 1 or 2, and that adding Galleri to standard-of-care screening about doubled the number of cancers detected. Hathaway also fears that if a patient gets a negative test result, they may think they can forgo screenings such as mammograms and colonoscopies. Rush and Grail caution that the test is not meant to replace routine screenings. Largely, though, she's concerned that the test is not yet approved by the FDA. Hathaway said she likes the idea of the test, but, 'I just don't think we're there yet.' 'I think more research needs to be done before we start offering it,' Hathaway said. So far, more than 380,000 people are or already have participated in studies of Galleri, according to Rush. That includes a recently completed trial with 140,000 participants in the United Kingdom. The company is also sponsoring a clinical trial that's now seeking to enroll an additional 50,000 Medicare beneficiaries to test whether Galleri can help find cancer early and decrease the number of late-stage cancer diagnoses. Though Galleri is not approved by the FDA, Grail said it has been granted breakthrough device designation by the agency, which is meant to speed up development and review of devices that can more effectively treat or diagnose life-threatening and debilitating conditions. The company expects to finish submitting information to the FDA next year for premarket approval. 'Now, for the first time we've got breakthrough technology that can find cancer in adults who have no idea they have cancer, they have no symptoms, there's no suspicion of cancer, and we can look for more than those five cancers,' said Dr. Joshua Ofman, president of Grail, referring to the cancers that now have recommended screening tools, such as mammograms for breast cancer and colonoscopies for colorectal cancer. 'We can look for all the other cancers that are taking people's lives, because when you can find cancer early that is your best chance to cure it,' Ofman. Many patients feel the same way. Peter Crowell, 65 of Bucktown, was among the first group of Rush patients to sign up this month to be tested. After his primary care doctor mentioned it, Crowell made an appointment to get his blood drawn. 'He asked me if I was interested, given my history, so I said, 'Yeah,'' Crowell said, noting he has a family history of cancer. 'It's just something I think I'd rather be proactive about.' Of course, Crowell wishes insurance would pay for it, but he's willing to shell out the $749 for the test. He said he'll likely pay for it using a flexible spending account. 'If I can find out if I have any of those markers, then it will be worth it,' Crowell said. Maggie Hornung, a nurse practitioner at Rush, recently had her blood drawn for the test. It takes about three to four weeks to get results. 'I obviously was excited as a provider to start offering this and working on this but as a patient I absolutely wanted to proceed,' said Hornung, 58. She wanted to take the test because she's had family members with cancer, and because of what she's seen in her work with patients in the high-risk breast cancer clinic at Rush. 'To me, $749 is a small cost compared to what things could be,' Hornung said.
Yahoo
4 days ago
- Business
- Yahoo
Why Cathie Wood Is Loading Up on This Hot Growth Stock (And Should You?)
In a market dominated by headlines about artificial intelligence (AI), cloud computing, and digital platforms, it is easy to overlook some of the most transformative developments in the life sciences. Cathie Wood, CEO of ARK Invest and known for her bold bets on disruptive innovation, has her sights set on Illumina (ILMN), a company that connects science and technology. On July 22, Wood's ARK's Genomic Revolution ETF (ARKG) bought 31,265 shares of Illumina, amounting to nearly $2.98 million, bringing the total investment in the company to $32 million. It is the ETF's 15th largest holding, comprising 2.8% of the overall portfolio. More News from Barchart UnitedHealth Stock Spirals Lower Again. Don't Buy the Dip. This Self-Driving Car Stock Is Surging on a Major Nvidia Boost Auto Revenue Keeps Plunging at Tesla. Should You Buy the TSLA Stock Dip or Run Far Away? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Let's find out if investors should follow Wood's lead and buy Illumina stock here. A High-Conviction Bet on the Future of Medicine Valued at $16.6 billion, Illumina is a biotechnology company that specializes in genome sequencing, or the process of reading and analyzing DNA. It manufactures machines (sequencers), software, and chemical kits that are used to decode the genetic material (DNA) of humans, animals, plants, and bacteria. Illumina's technology is used in hospitals and clinics, by cancer researchers, pharmaceutical companies, agricultural scientists, academics, and research institutions, among others. Some of its products include the NovaSeq X Series, iScan System, iSeq 100 System, Illumina DNA Prep, Illumina Stranded mRNA Prep, and many others. Illumina's stock price has dropped significantly since its 2021 highs, falling from above $500 to around the $100-$120 range by mid-2025. Much of this decline can be attributed to a series of self-inflicted wounds, most notably its controversial acquisition of cancer detection company Grail. However, with the Grail divestment in 2024 and a new CEO, Jacob Thaysen, in charge, Illumina appears to be refocusing on its core business of making genome sequencing cheaper, faster, and more accessible. Why the Timing Matters Now Wood is known for buying when volatility is high, particularly when she believes the market has overcorrected due to near-term concerns. Following the Grail divestment, leadership change, and a multi-quarter slump in revenue growth, investor sentiment is bearish on Illumina stock, explaining the nearly 20% drop year-to-date. However, Wood saw this as an opportunity to stock up on this rising genomic star. Illumina's financial performance appears to be stabilizing. For a growth investor like Wood, who prefers to overlook short-term earnings volatility in favor of long-term potential, these improvements are a welcome sign that the company is on the right track. In the first quarter, while revenue growth dipped slightly by 1.4%, the company improved its margins and reduced unnecessary expenses. Illumina exceeded revenue expectations and reaffirmed full-year guidance. Adjusted gross margins increased to 67.4% as a result of improved manufacturing efficiency and lower R&D costs. Adjusted earnings per share fell to $0.97 from $0.98 in the prior year's quarter. Remaining performance obligations (RPO) totaled $891 million, of which Illumina expects to generate 83% in revenue over the next year. With a reasonable debt-equity ratio of 0.63x, Illumina's balance sheet is stable. The company also generated a positive free cash flow of $208 million during the quarter. Illumina will report its second-quarter earnings on July 31. Analysts expect revenue of $1.05 billion on earnings per share of $1.01. Analysts predict a 3% drop in revenue for the full year but earnings growth of 72.9% to $4.24 per share, with an additional 9.5% increase expected in 2026. Another factor that may have influenced ARK's decision to increase its stake in Illumina is valuation. The stock is currently trading at 22 times forward earnings for 2026 and three times forward sales. Illumina has the world's largest genomics dataset, giving the company a competitive advantage. Many of Illumina's future revenue streams, including large-scale population sequencing contracts and new clinical applications in oncology and rare diseases, are not fully priced into current projections. This reasonable valuation represents a buying opportunity for a growth stock with excellent long-term prospects. What Is Wall Street Saying About Illumina Stock? Overall, the consensus on Illumina stock is a 'Moderate Buy.' Of the 22 analysts covering the stock, nine recommend a 'Strong Buy,' one suggests a 'Moderate Buy,' nine rate it a 'Hold,' one says it is a 'Moderate Sell,' and two have given it a 'Strong Sell' rating. The stock is trading close to its average target price of $106.83. However, the high price estimate of $185 suggests a rally of over 76.8% from current levels. The Key Takeaway Wood's stake in Illumina is a calculated investment based on extensive research, long-term vision, and a firm belief in the power of genomics to transform healthcare. Now, with a lower cost structure, a clear path back to profit growth, and exciting new products on the market, Illumina is poised for a turnaround. For investors with patience and a long horizon, Illumina stock represents a one-of-a-kind opportunity to invest in genomic infrastructure. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Medscape
5 days ago
- Health
- Medscape
MCED Tests in Primary Care: Proceed With Caution
Hi, everyone. I'm Dr Kenny Lin. I am a family physician and associate director of the Lancaster General Hospital Family Medicine Residency, and I blog at Common Sense Family Doctor. Kenneth W. Lin, MD, MPH In the past decade or so that I have been giving lectures on cancer screening at family medicine review courses, not much has changed. We screen for breast, cervical, and colorectal cancer in large numbers of people. We screen for lung cancer in current or past smokers over 50 years of age with at least a 20 pack-year history. We discuss the potential benefits and harms of screening for prostate cancer with older males. But these five cancer types represent a distinct minority of cancers. A 2022 study estimated that only 1 in 7 diagnosed cancer cases in the United States are caught by any of these screening tests, and 57% of cancers have no recommended screening tests, meaning that they are usually not detected until advanced stages. For the past few years, Grail has been selling a blood test that aims to fill the early detection gap by detecting cell-free DNA signals associated with cancer. At $949 per test, the Galleri test is advertised as being able to detect more than 50 cancer types in adults aged 50 years or older. Other companies are developing similar tests. If they haven't already, family physicians will soon be asked to order multicancer early detection (MCED) tests for patients or act on their results. So, what do we know about their benefits and harms? And what remains uncertain? A systematic review published in May 2025 by the Agency for Healthcare Research and Quality found that the evidence for MCED tests consists mostly of diagnostic accuracy studies with suboptimal designs. A few prospective studies have shown that the tests are highly specific but have relatively low sensitivity for early-stage cancers. There is little data on harms such as false alarms, incidental findings, and unnecessary diagnostic procedures and treatments; in one study, patient-reported anxiety associated with a positive MCED result was small and returned to baseline by 12 months, regardless of whether cancer was confirmed. To be effective, MCED tests must accurately detect cancer in asymptomatic people at stages early enough to decrease harm (by subjecting patients to less toxic cancer therapy) or increase benefits (by allowing patients to live longer or better). Already under-resourced primary care practices would need to develop new workflows to work up patients with positive tests and determine when to refer them to oncologists. In a JAMA Internal Medicine Special Communication, screening experts argued that since MCED screening 'would entail tremendous costs and potentially substantial harms", it should not be implemented until a randomized trial reports it reduces all-cause mortality. Others feel that a trial showing fewer cancer-related deaths, such as one being planned by the National Cancer Institute, would be sufficient. An ongoing trial of Galleri in more than 140,000 UK National Health Service patients expects to report effects on cancer stage-shift (a reduction in late stage cancer diagnoses) as early as next year, though it appears to have failed to meet criteria for early indications of benefit. Recognizing that diffusion of MCED tests into practice is outpacing the evidence, the American Cancer Society published a consensus statement to guide primary care clinicians. Important points include communicating uncertainty about benefits and harms, emphasizing that patients with negative results should continue to have all screenings recommended by the US Preventive Services Task Force, and first evaluating patients with positive results for cancer at the predicted tissue of origin (eg, mammography for breast cancer), then ordering total body PET-CT scans if the tissue of origin is unknown or the initial workup is unrevealing.
Web Release
6 days ago
- Business
- Web Release
Dynatrace Paves the Way to Autonomous Intelligence with its 3rd Generation Platform
Dynatrace Paves the Way to Autonomous Intelligence with its 3rd Generation Platform Dynatrace (NYSE: DT), the leading AI-powered observability platform, today announced significant advancements of its 3rd generation platform, enabling customers to unlock greater value of its capabilities. The platform is reimagining observability by combining the power of analytics, AI and automation to drive progress toward autonomous intelligence. Thousands of enterprise customers are already benefiting from the company's 3rd generation platform, helping organizations turn data into decisions and those decisions into immediate, intelligent action. Dynatrace addresses the demands of large, dynamic and complex business environments by redefining observability to extend beyond insights to deliver automations across IT, cloud, security and business operations. 'We are elevating the value of observability and building for the future of AI,' said Bernd Greifeneder, Founder and Chief Technology Officer at Dynatrace. 'The 3rd generation platform has been built to harness a goldmine of observability data in context and turn it into real-time knowledge for AI, creating actionable insights and automation, paving the way for autonomous intelligence.' Learn more: Dynatrace 3rd generation platform: Built for the world of Autonomous Intelligence, by Bernd Greifeneder, Founder and Chief Technology Officer at Dynatrace New capabilities available on the 3rd generation platform In today's digital economy, enterprises face an explosion of data across cloud-native architectures, distributed systems, and AI-driven applications. At the core of the Dynatrace 3rd generation platform is Grail, a massively parallel processing data lakehouse that seamlessly unifies observability, security, and business data. Combined with Dynatrace AI-driven analytics and automation, enterprises transform telemetry into precise business insights, and intelligent, automated actions across the organization. The new capabilities on the Dynatrace observability platform prioritize seamless operations across hybrid and multicloud environments to achieve measurable business outcomes. Key recent advancements include: · Cloud-Native and AI-Native Acceleration for Development: o Developers can easily ingest and analyze data from serverless and cloud architectures through self-service access. Dynatrace simplifies data visualizations for common cloud patterns and revolutionizes production debugging with the only live debugger that can scale to thousands of simultaneous developer sessions per tenant with non-breaking breakpoint for each session – with privacy protections. o The Dynatrace MCP server enables developers to bring real-time observability data directly into their AI-assisted development workflows to better inform designs, bolster security posture or debug issues without leaving their IDE. · Preventive Operations Powered by Agentic AI: o Davis AI automated root cause analysis and remediation are extended to include agentic AI capabilities for preventive operations and auto-remediation in complex scenarios involving multiple teams. This includes guided troubleshooting, interactive recommendations, and 'explain and summarize' natural language capabilities to minimize manual intervention and streamline collaboration between ITOps, SRE, Platform Engineering, DevSecOps and Development teams. o Davis CoPilot enables practitioners to use a natural language interface to accelerate advanced analytics, easily create workflows or dashboards, and integrate with other technologies and solutions. · Transformative Log Management Experience: o Dynatrace extends its unique capabilities to analyze all logs instantly – in context of other observability data – through enhancements to the Logs app and through Davis CoPilot engagement and explanations, unlocking insights and answers previously hidden in their data. o Dynatrace introduces flexible pricing options, with both retention and usage-based models, and always-on hot/hot storage with up to 10 years of retention. o Dynatrace achieves petabyte-per-day scale ingest and management, so businesses can now manage logs from across the enterprise at scale with simple, automatic context parsing. New, secure Kubernetes log collection simplifies setup for cloud native environments without the overhead and toil of legacy competitive solutions with complex telemetry silos, storage tiers, indexes, and schema definitions. 'With the volume of data worldwide expected to double over the next three years, plus increasingly dynamic and complex digital ecosystems and the rise of AI, businesses need solutions that do more than provide visibility,' said Steve Tack, Chief Product Officer at Dynatrace. 'Our newest capabilities are designed to drive proactive, intelligent automation that help entire teams across an organization connect the dots to better understand their digital systems and continuously improve business outcomes.' By integrating AI-powered systems with advanced automation, Dynatrace is helping customers turn data into action, driving outcomes that matter. 'The AI and predictive capabilities from Dynatrace were a differentiator,' said Jos Kerssens, Senior Vice President, IT Operations & Cloud Transformation at Air France-KLM. 'We're confident that any problem that arises can be dealt with quickly, dramatically reducing operational and revenue impact.' 'At TELUS, AI is fundamental to our digital transformation strategy, and our partnership with Dynatrace has been valuable in enhancing our capabilities,' said Kulvir Gahunia, Director, Site Reliability Office at TELUS. 'By combining our Agentic AI initiatives with Dynatrace's AI Observability capabilities, we've successfully optimized our development and operations workflows. This collaboration has enabled us to streamline incident resolution to minutes, from detection to pull requests. Through this integration of AI technologies, we're driving innovation and delivering measurable business impact while reducing downtime.' Dynatrace partnerships with industry leaders, such as DXC, further extend its impact. These partnerships provide customers with tailored solutions that can accelerate enterprise innovation and operational excellence, reinforcing Dynatrace's commitment to redefining business outcomes. 'By combining DXC's enterprise transformation expertise with Dynatrace's next-generation observability platform, we empower the world's leading brands to accelerate application modernization and harness the full power of AI-driven insights,' said James Taylor, Global General Manager, Enterprise Applications at DXC Technology. 'As Dynatrace's Global Partner of the Year, DXC is proud to lead the way in simplifying complexity, driving innovation, and enabling smarter, faster decision-making at scale.' 'Dynatrace 3rd generation observability platform represents a significant leap forward in managing the complexity of modern, cloud-native and AI-driven environments,' Rob Strechay, Managing Director & Principal Analyst Cloud Native, Data Platforms, Infrastructure, theCube Research. 'By unifying data and automating workflows with advanced AI capabilities, Dynatrace empowers enterprises to not only address operational challenges but also enable autonomous operations at scale. This approach is redefining how organizations turn complexity into clarity, unlocking new opportunities for innovation and driving measurable business outcomes.' Additional Resources · Video: Explore the newest Dynatrace platform capabilities paving the way to autonomous intelligence with CTO Bernd Greifeneder, Dana Harrison, Principal Site Reliability Engineer, TELUS, Kulvir Gahunia, Director Site Reliability, TELUS and Rob Strechay, Managing Director & Principal Analyst Cloud Native, Data Platforms, Infrastructure, theCube Research. · Blog: Dynatrace 3rd generation platform: Built for the world of Autonomous Intelligence, by Bernd Greifeneder, Founder and Chief Technology Officer at Dynatrace · Video: Defining Observability for What Comes Next · Video: Why the Dynatrace 3rd Gen Platform Matters for Development Teams · Video: Cloud-Native at Scale Requires Intelligence
Zawya
7 days ago
- Business
- Zawya
Dynatrace paves the way to autonomous intelligence with its 3rd generation platform
Dubai, UAE — Dynatrace (NYSE: DT), the leading AI-powered observability platform, today announced significant advancements of its 3rd generation platform, enabling customers to unlock greater value of its capabilities. The platform is reimagining observability by combining the power of analytics, AI and automation to drive progress toward autonomous intelligence. Thousands of enterprise customers are already benefiting from the company's 3rd generation platform, helping organizations turn data into decisions and those decisions into immediate, intelligent action. Dynatrace addresses the demands of large, dynamic and complex business environments by redefining observability to extend beyond insights to deliver automations across IT, cloud, security and business operations. 'We are elevating the value of observability and building for the future of AI,' said Bernd Greifeneder, Founder and Chief Technology Officer at Dynatrace. 'The 3rd generation platform has been built to harness a goldmine of observability data in context and turn it into real-time knowledge for AI, creating actionable insights and automation, paving the way for autonomous intelligence.' New capabilities available on the 3rd generation platform In today's digital economy, enterprises face an explosion of data across cloud-native architectures, distributed systems, and AI-driven applications. At the core of the Dynatrace 3rd generation platform is Grail, a massively parallel processing data lakehouse that seamlessly unifies observability, security, and business data. Combined with Dynatrace AI-driven analytics and automation, enterprises transform telemetry into precise business insights, and intelligent, automated actions across the organization. The new capabilities on the Dynatrace observability platform prioritize seamless operations across hybrid and multicloud environments to achieve measurable business outcomes. Key recent advancements include: Cloud-Native and AI-Native Acceleration for Development: Developers can easily ingest and analyze data from serverless and cloud architectures through self-service access. Dynatrace simplifies data visualizations for common cloud patterns and revolutionizes production debugging with the only live debugger that can scale to thousands of simultaneous developer sessions per tenant with non-breaking breakpoint for each session – with privacy protections. The Dynatrace MCP server enables developers to bring real-time observability data directly into their AI-assisted development workflows to better inform designs, bolster security posture or debug issues without leaving their IDE. Preventive Operations Powered by Agentic AI: Davis AI automated root cause analysis and remediation are extended to include agentic AI capabilities for preventive operations and auto-remediation in complex scenarios involving multiple teams. This includes guided troubleshooting, interactive recommendations, and 'explain and summarize' natural language capabilities to minimize manual intervention and streamline collaboration between ITOps, SRE, Platform Engineering, DevSecOps and Development teams. Davis CoPilot enables practitioners to use a natural language interface to accelerate advanced analytics, easily create workflows or dashboards, and integrate with other technologies and solutions. Transformative Log Management Experience: Dynatrace extends its unique capabilities to analyze all logs instantly - in context of other observability data – through enhancements to the Logs app and through Davis CoPilot engagement and explanations, unlocking insights and answers previously hidden in their data. Dynatrace introduces flexible pricing options, with both retention and usage-based models, and always-on hot/hot storage with up to 10 years of retention. Dynatrace achieves petabyte-per-day scale ingest and management, so businesses can now manage logs from across the enterprise at scale with simple, automatic context parsing. New, secure Kubernetes log collection simplifies setup for cloud native environments without the overhead and toil of legacy competitive solutions with complex telemetry silos, storage tiers, indexes, and schema definitions. 'With the volume of data worldwide expected to double over the next three years, plus increasingly dynamic and complex digital ecosystems and the rise of AI, businesses need solutions that do more than provide visibility,' said Steve Tack, Chief Product Officer at Dynatrace. 'Our newest capabilities are designed to drive proactive, intelligent automation that help entire teams across an organization connect the dots to better understand their digital systems and continuously improve business outcomes.' By integrating AI-powered systems with advanced automation, Dynatrace is helping customers turn data into action, driving outcomes that matter. 'The AI and predictive capabilities from Dynatrace were a differentiator,' said Jos Kerssens, Senior Vice President, IT Operations & Cloud Transformation at Air France-KLM. 'We're confident that any problem that arises can be dealt with quickly, dramatically reducing operational and revenue impact.' 'At TELUS, AI is fundamental to our digital transformation strategy, and our partnership with Dynatrace has been valuable in enhancing our capabilities,' said Kulvir Gahunia, Director, Site Reliability Office at TELUS. 'By combining our Agentic AI initiatives with Dynatrace's AI Observability capabilities, we've successfully optimized our development and operations workflows. This collaboration has enabled us to streamline incident resolution to minutes, from detection to pull requests. Through this integration of AI technologies, we're driving innovation and delivering measurable business impact while reducing downtime.' Dynatrace partnerships with industry leaders, such as DXC, further extend its impact. These partnerships provide customers with tailored solutions that can accelerate enterprise innovation and operational excellence, reinforcing Dynatrace's commitment to redefining business outcomes. 'By combining DXC's enterprise transformation expertise with Dynatrace's next-generation observability platform, we empower the world's leading brands to accelerate application modernization and harness the full power of AI-driven insights,' said James Taylor, Global General Manager, Enterprise Applications at DXC Technology. 'As Dynatrace's Global Partner of the Year, DXC is proud to lead the way in simplifying complexity, driving innovation, and enabling smarter, faster decision-making at scale.' "Dynatrace 3rd generation observability platform represents a significant leap forward in managing the complexity of modern, cloud-native and AI-driven environments,' Rob Strechay, Managing Director & Principal Analyst Cloud Native, Data Platforms, Infrastructure, theCube Research. 'By unifying data and automating workflows with advanced AI capabilities, Dynatrace empowers enterprises to not only address operational challenges but also enable autonomous operations at scale. This approach is redefining how organizations turn complexity into clarity, unlocking new opportunities for innovation and driving measurable business outcomes.' Additional Resources Video: Explore the newest Dynatrace platform capabilities paving the way to autonomous intelligence with CTO Bernd Greifeneder, Dana Harrison, Principal Site Reliability Engineer, TELUS, Kulvir Gahunia, Director Site Reliability, TELUS and Rob Strechay, Managing Director & Principal Analyst Cloud Native, Data Platforms, Infrastructure, theCube Research. Blog: Dynatrace 3rd generation platform: Built for the world of Autonomous Intelligence, by Bernd Greifeneder, Founder and Chief Technology Officer at Dynatrace Video: Defining Observability for What Comes Next Video: Why the Dynatrace 3rd Gen Platform Matters for Development Teams Video: Cloud-Native at Scale Requires Intelligence About Dynatrace Dynatrace is advancing observability for today's digital businesses, helping to transform the complexity of modern digital ecosystems into powerful business assets. By leveraging AI-powered insights, Dynatrace enables organizations to analyze, automate, and innovate faster to drive their business forward. Cautionary Language Concerning Forward-Looking Statements This press release includes certain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Dynatrace's capabilities and platform and the expected current and future benefits to organizations from using the Dynatrace platform. These forward-looking statements include all statements that are not historical facts and statements identified by words such as 'will,' 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and words of similar meaning. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies, and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including the risks set forth under the caption 'Risk Factors' in our Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, and our other SEC filings. We assume no obligation to update any forward-looking statements contained in this document as a result of new information, future events, or otherwise.
